Heptavalent pneumococcal conjugate vaccine: current and future impact.
Diseases caused by Streptococcus pneumoniae contribute significantly to worldwide morbidity and mortality. S. pneumoniae is now the number one cause of invasive bacterial disease in children in countries where Haemophilus influenzae type b (Hib) disease has been conquered by use of the Hib conjugate vaccine. Licensure of a heptavalent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children less than 5 years old in the USA represents the culmination of more than five decades of pneumococcal vaccine development. This review will: highlight safety, immunogenicity and efficacy studies that led to US Food and Drug Administration approval of this PCV7; summarize data about the incidence of childhood pneumococcal disease in the USA subsequent to licensure; review PCV7 treatment guidelines currently in place in the USA, Canada and Australia; and consider future directions in pneumococcal vaccine research.
Hsu
Katherine K
KK
Boston University Medical Center, Section of Pediatric Infectious Diseases, 774 Albany Street, Finland Labs 5th Floor, Boston, MA 02118-2393, USA. khsu@bu.edu
Pelton
Stephen I
SI
D002648:Child; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D017589:Immunization Programs / Q000706:statistics & numerical data / Q000639:trends; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D017410:Practice Guidelines as Topic; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014481:United States
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022401:Meningococcal Vaccines; D022242:Pneumococcal Vaccines